Module 3: When the In Vitro Micronucleus Is Positive: What It Means and How to Move Forward

Recorded On: 04/22/2027

image
image


This presentation provides an overview of the steps to take when navigating a positive or equivocal in vitro micronucleus test result, including how to utilize relevant regulatory guidance to guide data interpretation and follow-up strategies. The presentation covers how to assess the biological relevance of a positive result and evaluate potential nongenotoxic contributing factors. Methodological approaches to determine the mechanism of action are discussed, including approaches to distinguish between clastogens and aneugens, as well as how to determine potential nonlinear safety thresholds. A real-world case study is shared to illustrate how to address conflicting in vitro and in vivo results within a regulatory submission and strategic decision making to get a program back on track.

Sucheta Mukherjee, PhD, DABT

Sucheta Mukherjee, PhD, DABT

Principal Scientist - Toxicologist

Genentech, Inc.

Dr. Sucheta Mukherjee is a board-certified Principal Scientist - Toxicologist at Genentech, Inc., where she designs and oversees nonclinical toxicology programs for small molecule, large molecule, and oligonucleotide discovery and development in oncology, neuroscience, immunology, and ophthalmology indications. She previously worked at Aligos Therapeutics, Inc. (2019–2023) as a project toxicologist for small molecule and oligonucleotide programs focused on liver diseases. She received her doctorate in Pharmacology/Toxicology from the University of California, Davis in 2015 and was a DoD Horizon Award postdoctoral fellow at the University of California, San Francisco from 2016–2019. Dr. Mukherjee has been a member of ACT since 2020, where she served on the Early Career Professionals Subcommittee (ECPSC) from 2020–2023 and is currently serving as an elected member of the Education Committee (EdCom; 2025–present). Within ACT, she co-chaired one annual meeting session in 2021, co-hosted two ECP webinars on IND submissions (2021) and communication for toxicologists (2022), and was a panelist in a 2023 leadership webinar. In 2023, she co-led a mentorship focus group as part of the existing ACT mentorship platform on InterACT as well as outreach initiatives for member and non-member ECPs. As a part of EdCom, she contributes to the planning and implementation of all ACT educational opportunities including the Continuing Education (CE) program for the Annual Meeting, classroom-based courses, online courses, webinars, and podcasts. She is also actively involved in the Northern California Regional Chapter of SOT. She served as Treasurer from 2021–2023 and currently serves as Past President (as a part of the presidential chain; 2023–present), providing guidance to the NorCal SOT Board of Directors as they plan symposia and career development opportunities for the membership, which encompasses toxicologists from academia, CROs, industry, and government. Dr. Mukherjee is also an active member of the IQ DruSafe RNA Therapeutics Working Group curating surveys, presentations and publications for nonclinical strategies for oligonucleotide drug development. Dr. Mukherjee has co-authored nine publications and presented her work at ACT and SOT as well as several other national conferences, but her interest in genetic toxicology stems all the way back to her undergraduate research days studying mechanisms of DNA damage response.

Key:

Complete
Failed
Available
Locked
Module 3: When the In Vitro Micronucleus Is Positive: What It Means and How to Move Forward
Module 3: When the In Vitro Micronucleus Is Positive: What It Means and How to Move Forward, Sucheta Mukherjee, PhD, DABT
Recorded 04/22/2027  |  90 minutes
Recorded 04/22/2027  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.